The limited experiences of targeted therapies for the treatment of SCLC regard almost exclusively the use of EGFR and ALK inhibitors (EGFRis and ALKis) in the presence of specific molecular alterations of the corresponding genes. Here, EGFR is linked to small cell lung carcinoma.